MX2012013374A - Tratamiento de infecciones de clostridium difficile en pacientes bajo terapia con antibioticos. - Google Patents
Tratamiento de infecciones de clostridium difficile en pacientes bajo terapia con antibioticos.Info
- Publication number
- MX2012013374A MX2012013374A MX2012013374A MX2012013374A MX2012013374A MX 2012013374 A MX2012013374 A MX 2012013374A MX 2012013374 A MX2012013374 A MX 2012013374A MX 2012013374 A MX2012013374 A MX 2012013374A MX 2012013374 A MX2012013374 A MX 2012013374A
- Authority
- MX
- Mexico
- Prior art keywords
- clostridium difficile
- treatment
- antibiotic therapy
- difficile infection
- patients undergoing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Abstract
Métodos para tratar una infección de Clostridium difficile en un sujeto que está recibiendo una terapia con antibióticos para combatir una infección diferente, que comprenden administrarle al sujeto una cantidad eficaz de un compuesto como los que se describen en la presente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34591510P | 2010-05-18 | 2010-05-18 | |
PCT/US2011/037003 WO2011146621A2 (en) | 2010-05-18 | 2011-05-18 | Treatment of clostridium difficile infection in patients undergoing antibiotic therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2012013374A true MX2012013374A (es) | 2013-05-06 |
Family
ID=44992319
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012013374A MX2012013374A (es) | 2010-05-18 | 2011-05-18 | Tratamiento de infecciones de clostridium difficile en pacientes bajo terapia con antibioticos. |
Country Status (9)
Country | Link |
---|---|
US (1) | US20130331347A1 (es) |
AU (1) | AU2011255630B2 (es) |
BR (1) | BR112012029259A8 (es) |
CA (1) | CA2799386A1 (es) |
CL (1) | CL2012003201A1 (es) |
CO (1) | CO6670518A2 (es) |
MX (1) | MX2012013374A (es) |
PE (1) | PE20130310A1 (es) |
WO (1) | WO2011146621A2 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2826662A1 (en) * | 2011-02-04 | 2012-08-09 | Optimer Pharmaceuticals, Inc. | Treatment of bacterial infections |
RU2015140498A (ru) * | 2013-03-08 | 2017-04-13 | Сипла Лимитед | Фармацевтические композиции для ректального введения |
CN103275152B (zh) * | 2013-05-29 | 2015-11-18 | 华北制药集团新药研究开发有限责任公司 | 一种高纯度非达霉素的制备方法 |
CN103920017B (zh) * | 2014-05-09 | 2016-08-17 | 马金风 | 一种治疗宫颈炎的药物组合物 |
CN104098637B (zh) * | 2014-07-09 | 2017-01-04 | 浙江海正药业股份有限公司 | 一种纯化非达霉素的方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0511119A (pt) * | 2004-05-14 | 2007-11-27 | Optimer Pharmaceuticals Inc | tratamento de doenças associadas com o uso de antibióticos |
US7906489B2 (en) * | 2004-05-14 | 2011-03-15 | Optimer Pharmaceuticals, Inc. | 18-membered macrocycles and analogs thereof |
US20080176927A1 (en) * | 2007-01-19 | 2008-07-24 | Optimer Pharmaceuticals, Inc. | Compositions of stable tiacumicins |
-
2011
- 2011-05-18 AU AU2011255630A patent/AU2011255630B2/en active Active
- 2011-05-18 BR BR112012029259A patent/BR112012029259A8/pt not_active IP Right Cessation
- 2011-05-18 MX MX2012013374A patent/MX2012013374A/es not_active Application Discontinuation
- 2011-05-18 PE PE2012002183A patent/PE20130310A1/es not_active Application Discontinuation
- 2011-05-18 CA CA2799386A patent/CA2799386A1/en not_active Abandoned
- 2011-05-18 WO PCT/US2011/037003 patent/WO2011146621A2/en active Application Filing
-
2012
- 2012-11-16 CO CO12208169A patent/CO6670518A2/es not_active Application Discontinuation
- 2012-11-16 CL CL2012003201A patent/CL2012003201A1/es unknown
-
2013
- 2013-06-28 US US13/930,969 patent/US20130331347A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CL2012003201A1 (es) | 2013-07-05 |
PE20130310A1 (es) | 2013-04-06 |
BR112012029259A8 (pt) | 2021-03-23 |
AU2011255630B2 (en) | 2015-04-30 |
US20130331347A1 (en) | 2013-12-12 |
AU2011255630A1 (en) | 2013-01-10 |
WO2011146621A9 (en) | 2012-04-12 |
CO6670518A2 (es) | 2013-05-15 |
WO2011146621A2 (en) | 2011-11-24 |
BR112012029259A2 (pt) | 2021-03-02 |
CA2799386A1 (en) | 2011-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA115231C2 (uk) | Сполуки імідазопіролідинонів | |
UA110473C2 (uk) | Спосіб лікування раку за допомогою пухлиноасоційованого антигену, отриманого із цикліну d1 | |
AU2011328009A8 (en) | Compounds and methods for treating pain | |
PH12014502048B1 (en) | Treatment of cancer with tor kinase inhibitors | |
PH12015500954B1 (en) | Device for extracorporeal blood treatment | |
PH12014502046A1 (en) | Treatment of cancer with tor kinase inhibitors | |
MX343931B (es) | Tratamiento de la esclerosis lateral amiotrofica con el uso de celulas derivadas del cordon umbilical. | |
MX2013009256A (es) | Metodo para inhibir las celulas tumorales hamartoma. | |
MX348184B (es) | Métodos y composiciones para tratar diarrea asociada con vih. | |
SG10201810575WA (en) | Treatment of prostate cancer with tor kinase inhibitors | |
MX2012013374A (es) | Tratamiento de infecciones de clostridium difficile en pacientes bajo terapia con antibioticos. | |
MX2013010050A (es) | Inhibidor de proteasoma delanzomib para uso en el tratamiento de lupus. | |
PH12014502065A1 (en) | Vesicular formulations | |
MX2013010367A (es) | Composiciones y metodos para la terapia y diagnostico de influenza. | |
WO2011133826A3 (en) | Method for treating pancreatic cancer | |
MX2014003873A (es) | Metodo para tratar el carcinoma mucoepidermoide. | |
MX2012013372A (es) | Metodos para tratar infecciones bacterianas recurrentes. | |
TN2014000418A1 (en) | Methods for treating cancer using pi3k inhibitor and mek inhibitor | |
MX2014013491A (es) | Metodos para mantener, tratar o mejorar la funcion cognitiva. | |
WO2012075210A3 (en) | Method for treating refractory cancer | |
WO2011133479A3 (en) | Combination therapy with a proteasome inhibitor and a gallium complex | |
EA201491629A1 (ru) | Способы лечения рака с использованием липоплатина | |
UA71871U (ru) | Способ диагностики эффективности антибиотикотерапии у больных лайм-борелиозом | |
UA105429C2 (ru) | Способ лечения опухолевых образований | |
UA60230U (ru) | Способ лечения необратимых форм пульпитов |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or rights |
Owner name: MERCK SHARP & DOHME CORP.* |
|
HC | Change of company name or juridical status |
Owner name: SOLENIS TECHNOLOGIES CAYMAN, L.P. |
|
FA | Abandonment or withdrawal |